Gene Therapy for Human Genetic Disease?, Science, vol.175, issue.4025, pp.949-955, 1972. ,
DOI : 10.1126/science.175.4025.949
Report and recommendations of the panel to assess the NIH investment in research on gene therapy, 1995. ,
The AAV Vector Toolkit: Poised at the Clinical Crossroads, Molecular Therapy, vol.20, issue.4, pp.699-708, 2012. ,
DOI : 10.1038/mt.2011.287
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus, Cell, vol.33, issue.1, pp.153-159, 1983. ,
DOI : 10.1016/0092-8674(83)90344-6
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector, Science, vol.272, issue.5259, pp.263-267, 1996. ,
DOI : 10.1126/science.272.5259.263
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, pp.669-672, 2000. ,
DOI : 10.1126/science.288.5466.669
Correction of ADA- SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, vol.296, pp.2410-2413, 2002. ,
Cavazzana-Calvo, Efficacy of gene therapy for X-linked severe combined immunodeficiency, N. Engl. J. Med, pp.363-355, 2010. ,
Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency, Science Translational Medicine, vol.3, issue.97, p.79, 2011. ,
DOI : 10.1126/scitranslmed.3002715
Cavazzana-Calvo, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, vol.302, pp.415-419, 2003. ,
Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined Immunodeficiency, Molecular Therapy, vol.16, issue.3, pp.590-598, 2008. ,
DOI : 10.1038/sj.mt.6300393
A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency, N. Engl. J. Med, pp.371-1407, 2014. ,
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, p.1233151, 2013. ,
DOI : 10.1126/science.1233151
Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, JAMA, vol.313, pp.1550-1563, 2015. ,
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy, Science, vol.326, pp.818-823, 2009. ,
URL : https://hal.archives-ouvertes.fr/cea-00817492
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection, Blood, vol.117, issue.20, pp.5332-5339, 2011. ,
DOI : 10.1182/blood-2010-09-306761
Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia, Nature, vol.467, pp.318-322, 2010. ,
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response, Nat. Med, pp.12-342, 2006. ,
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B, New England Journal of Medicine, vol.371, issue.21, p.371, 1994. ,
DOI : 10.1056/NEJMoa1407309
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness, New England Journal of Medicine, vol.372, issue.20, pp.372-1920, 2015. ,
DOI : 10.1056/NEJMoa1412965
Long-Term Effect of Gene Therapy on Leber???s Congenital Amaurosis, New England Journal of Medicine, vol.372, issue.20, pp.372-1887, 2015. ,
DOI : 10.1056/NEJMoa1414221
Long-Term Effects of Retinal Gene Therapy in Childhood Blindness, New England Journal of Medicine, vol.372, issue.20, pp.1954-1955, 2015. ,
DOI : 10.1056/NEJMe1503419
Gene therapy returns to centre stage, Nature, vol.32, issue.7573, pp.351-360, 2015. ,
DOI : 10.1038/nature15818
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, New England Journal of Medicine, vol.371, issue.16, pp.371-1507, 2014. ,
DOI : 10.1056/NEJMoa1407222
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Mackall, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, pp.517-528, 2015. ,
DOI : 10.1016/S0140-6736(14)61403-3
The new frontier of genome engineering with CRISPR-Cas9, Science, vol.346, issue.6213, p.1258096, 2014. ,
DOI : 10.1126/science.1258096
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV, N. Engl. J. Med, vol.370, pp.901-910, 2014. ,
Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy, Science, vol.351, issue.6271, pp.400-403, 2016. ,
DOI : 10.1126/science.aad5725
Targeted genome editing in human repopulating haematopoietic stem cells, Targeted genome editing in human repopulating haematopoietic stem cells, pp.235-240, 2014. ,
DOI : 10.1038/nature13420
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo, Nature Biotechnology, vol.33, issue.3, pp.34-328, 2016. ,
DOI : 10.1371/journal.pone.0108424
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice, Nature Biotechnology, vol.246, issue.3, pp.34-334, 2016. ,
DOI : 10.1038/gt.2011.111